Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase IIIb, interventional, single arm, multicentre study to evaluate safety,
effectivenees, use of resources and patient reporting outcomes in patients with ES-SCLC
treated with durvalumab in combination with platinum-etoposide as first-line treatment in
Spain.